To enable treatment with TRK-inhibitors in case of incurable recurrent or metastatic disease detection of NTRK fusions is pivotal, for which pan-TRK IHC is often used as initial screening prior to NGS. The gene discussed is NTRK1; the disease is metastatic neoplasm.